Evidence map›Paper›PMID 32215634›Full record

ArticleJAMA network open2020

Association of Race and Ethnicity With Late-Life Depression Severity, Symptom Burden, and Care.

Chirag M Vyas, Macarius Donneyong, David Mischoulon, Grace Chang, Heike Gibson, Nancy R Cook, JoAnn E Manson, Charles F Reynolds, Olivia I Okereke

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Chirag M VyasDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.
Macarius DonneyongCollege of Pharmacy, The Ohio State University, Columbus.
David MischoulonDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.
Grace ChangDepartment of Psychiatry, VA Boston Healthcare System, Brockton, Massachusetts.
Heike GibsonDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Nancy R CookDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
JoAnn E MansonDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Charles F ReynoldsDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Olivia I OkerekeDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.
Brigham and Women's Hospital · USHarvard University · USMassachusetts General Hospital · USThe Ohio State University · USUniversity of Pittsburgh · USVA Boston Healthcare System · US

Funding

VITamin D and omegA-3 triaL (VITAL)U01CA138962 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., MANSON, JOANN ELISABETH · 2009 to 2014
$23.6M
The VITamin D and OmegA-3 TriaL (VITAL)R01CA138962 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., MANSON, JOANN ELISABETH · 2015 to 2019
$20.9M
RESEARCH METHODS COREP30MH090333 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REYNOLDS, CHARLES F. · 2011 to 2015
$8.3M
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaLR01MH091448 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI OKEREKE, OLIVIA IFEOMA · 2010 to 2019
$6.5M
Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Joint PainR01AR059086 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2010 to 2021
$5.4M
Randomized trial of vitamin D and omega-3 fatty acids for diabetic kidney diseaseR01DK088762 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2019
$4.7M
Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and HypertensionR01HL102122 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FORMAN, JOHN P, SESSO, HOWARD D · 2011 to 2016
$3.3M
Lung VITamin D and OmegA-3 TriaL (Lung VITAL)R01HL101932 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLD, DIANE R · 2010 to 2014
$3.2M
A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive DeclineR01AG036755 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI KANG, JAE H · 2010 to 2015
$2.6M
Diabetes Prevention in the Vitamin D and Omega-3 TrialR01DK088078 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI PRADHAN, ARUNA DAS, SONG, YIQING · 2010 to 2014
$2.4M
Vitamin D and Omega-3 Fatty Acids(VITAL Trial): Effects on FracturesR01AR060574 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI LEBOFF, MERYL SUSAN · 2010 to 2013
$779k
NCI NIH HHS R01 CA138962NCI NIH HHS U01 CA138962NHLBI NIH HHS R01 HL101932NHLBI NIH HHS R01 HL102122NIAMS NIH HHS R01 AR059086NIAMS NIH HHS R01 AR060574NIA NIH HHS R01 AG036755NIDDK NIH HHS R01 DK088078NIDDK NIH HHS R01 DK088762NIMH NIH HHS P30 MH090333NIMH NIH HHS R01 MH091448
6 · The paper itself

Abstract

Importance: Knowledge gaps persist regarding racial and ethnic variation in late-life depression, including differences in specific depressive symptoms and disparities in care. Objective: To examine racial/ethnic differences in depression severity, symptom burden, and care. Design, Setting, and Participants: This cross-sectional study included 25 503 of 25 871 community-dwelling older adults who participated in the Vitamin D and Omega-3 Trial (VITAL), a randomized trial of cancer and cardiovascular disease prevention conducted from November 2011 to December 2017. Data analysis was conducted from June to September 2018. Exposure: Racial/ethnic group (ie, non-Hispanic white; black; Hispanic; Asian; and other, multiple, or unspecified race). Main Outcomes and Measures: Depressive symptoms, assessed using the Patient Health Questionnaire-8 (PHQ-8); participant-reported diagnosis, medication, and/or counseling for depression. Differences across racial/ethnic groups were evaluated using multivariable zero-inflated negative binomial regression to compare PHQ-8 scores and multivariable logistic regression to estimate odds of item-level symptom burden and odds of depression treatment among those with diagnosed depression. Results: There were 25 503 VITAL participants with adequate depression data (mean [SD] age, 67.1 [7.1] years) including 12 888 [50.5%] women, 17 828 [69.9%] non-Hispanic white participants, 5004 [19.6%] black participants, 1001 [3.9%] Hispanic participants, 377 [1.5%] Asian participants, and 1293 participants [5.1%] who were categorized in the other, multiple, or unspecified race group. After adjustment for sociodemographic, lifestyle, and health confounders, black participants had a 10% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (rate ratio [RR], 1.10; 95% CI, 1.04-1.17; P < .001); Hispanic participants had a 23% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (RR, 1.23; 95% CI, 1.10-1.38; P < .001); and participants in the other, multiple, or unspecified group had a 14% higher severity level of PHQ-8 scores compared with non-Hispanic white participants (RR, 1.14; 95% CI, 1.04-1.25; P = .007). Compared with non-Hispanic white participants, participants belonging to minority groups had 1.5-fold to 2-fold significantly higher fully adjusted odds of anhedonia (among black participants: odds ratio [OR], 1.76; 95% CI, 1.47-2.11; among Hispanic participants: OR, 1.96; 95% CI, 1.43-2.69), sadness (among black participants: OR, 1.31; 95% CI, 1.07-1.60; among Hispanic participants: OR, 2.09; 95% CI, 1.51-2.88), and psychomotor symptoms (among black participants: OR, 1.77; 95% CI, 1.31-2.39; among Hispanic participants: OR, 2.12; 95% CI, 1.28-3.50); multivariable-adjusted odds of sleep problems and guilt appeared higher among Hispanic vs non-Hispanic white participants (sleep: OR, 1.24; 95% CI, 1.01-1.52; guilt: 1.84; 95% CI, 1.31-2.59). Among those with clinically significant depressive symptoms (ie, PHQ-8 score ≥10) and/or those with diagnosed depression, black participants were 61% less likely to report any treatment (ie, medications and/or counseling) than non-Hispanic white participants after adjusting for confounders (adjusted OR, 0.39; 95% CI, 0.27-0.56). Conclusions and Relevance: In this cross-sectional study, significant racial and ethnic differences in late-life depression severity, item-level symptom burden, and depression care were observed after adjustment for numerous confounders. These findings suggest a need for further examination of novel patient-level and clinician-level factors underlying these associations.

Indexed as

AgedCost of IllnessCross-Sectional StudiesDepressionEthnicityHealth Status DisparitiesHealth SurveysHumansMiddle AgedRacial Groups

Identifiers

PMID32215634
PMCPMC7325738
OpenAlexW3013606243

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.